Page 1

888C4 Therapeutics C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results November 10 , 2021 - Phase 1/2 study of CFT7455 , a Novel IKZF1 / 3 Degrader , Progressing with Data Expected in 2022 ; Trial - in - Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting - - Investigational New Drug ( IND ) Application for CFT8634 , a Degrader Targeting BRD9 for the Treatment of Synovial Sarcoma and SMARCB1 - null Tumors , On Track for Submission by YE 2021 - - Development Candidate CFT1946 , a BRAF V600X Degrader , in IND - enabling Activities ; C4T to Advance CFT1946 Independently- - On Track to Deliver Four Clinical - stage Programs by YE 2022 - WATERTOWN , Mass . , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- C4 Therapeutics , Inc. ( C4T ) ( Nasdaq : CCCC ) , a clinical - stage biopharmaceutical company pioneering a new class of small - molecule medicines that selectively destroy disease - causing proteins through degradation , today reported business highlights and financial results for the third quarter of 2021 . " In recent months , C4T has built momentum across our portfolio of highly potent targeted protein degraders by continuing to enroll patients in our CFT7455 Phase 1/2 clinical trial and successfully nominating our next development candidate , CFT1946 , a BRAF V600X degrader for the treatment of V600 mutant solid tumors " said Andrew Hirsch , chief executive officer of C4 Therapeutics . " We remain on track to achieve our remaining 2021 milestones , including IND submission for CFT8634 and advancing our EGFR and BRAF degraders towards the clinic . Our strong balance sheet and commitment to bringing innovative treatments to patients keep us on track to deliver clinical data for CFT7455 next year and achieve four clinical programs by end of 2022. " THIRD QUARTER 2021 AND RECENT BUSINESS HIGHLIGHTS CFT7455 : CFT7455 is an orally bioavailable MonoDACTM degrader targeting IKZF1 / 3 for the treatment of multiple myeloma and non - Hodgkin's lymphomas , including peripheral T - cell lymphoma and mantle cell lymphoma . • Accepted to Present at the 63rd American Society of Hematology ( ASH ) Annual Meeting & Exposition : Jesus G. Berdeja , M.D. , director , multiple myeloma research at Sarah Cannon Research Institute , will present a trial - in - progress poster titled " A Phase 1 Study of CFT7455 , a Novel Degrader of IKZF1 / 3 , in Multiple Myeloma and Non - Hodgkin Lymphoma " at the ASH Annual Meeting at 5:30 p.m. ET on Saturday , December 11 , 2021. The November online supplemental issue of Blood also features the abstract . • Received Orphan Drug Designation : In August 2021 , the U.S. Food and Drug Administration granted Orphan Drug Designation to CFT7455 for the treatment of multiple myeloma . CFT8634 : CFT8634 is an orally bioavailable BiDAC ™ degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1 - null solid tumors . • Presented at the 4th Annual Targeted Protein Degradation Summit : In October 2021 , C4T delivered a presentation describing the multiparameter optimization of a series of BRD9 degraders , which led to the identification of a degrader with a sufficient intravenous pharmacokinetic ( PK ) profile to enable in vivo proof - of - concept studies . This work served as a launching point for further optimization and eventually led to the discovery of CFT8634 , an orally bioavailable BiDAC degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1 - null solid tumors . CFT8919 : CFT8919 is a potent and selective BiDAC degrader of EGFR L858R for the treatment of non - small cell lung cancer ( NSCLC ) . • Presented at the 4th Annual Targeted Protein Degradation Summit : In October 2021 , C4T delivered an encore presentation of the Company's June presentation at the Keystone Symposium on targeted protein degradation . The presentation included pre - clinical data demonstrating CFT8919 is active in in vitro and in vivo models of acquired resistance to approved EGFR inhibitors which harbor resistance - causing secondary mutations in EGFR . CFT1946 : CFT1946 is an orally bioavailable , mutant - selective BiDAC degrader targeting BRAF V600X . • Nominated CFT1946 for Clinical Development : In August 2021 , C4T and Roche selected CFT1946 , a mutant - selective degrader of BRAF V600X active preclinically in the setting of acquired resistance to BRAF inhibitors , as a development candidate . C4T has initiated IND - enabling activities for CFT1946 .